FeesSafety
Pluang+

KR1 plc starts staking 5,000 Bittensor tokens, targeting 6.6% annualized income from AI blockchain infrastructure.

Protocol Fundamentals
29 Oct 2026, 13:52 WIB
Tokenpost
View Source
Bullish
KR1 plc starts staking 5,000 Bittensor tokens, targeting 6.6% annualized income from AI blockchain infrastructure.

KR1 plc has begun staking 5,000 Bittensor (TAO) tokens as part of its digital asset infrastructure strategy, aiming to generate an estimated 6.6% annualized income based on current reward rates. Bittensor is a layer-1 blockchain supporting AI-related services, where independent providers compete for rewards by delivering computing and AI inference services. KR1 uses validators to assess providers and share in network rewards, with the flexibility to access staked tokens immediately after unstaking. The company plans to report its holdings and income monthly and sees growing demand for AI infrastructure as software complexity increases, aiming to boost both asset value and income per share.

KR1's recent staking of Bittensor's TAO token is context for readers. For those watching the broader crypto market, 7 of 50 major cryptocurrencies rose while 42 fell as of Oct 29, 2026 17:53 WIB. Notable movers include AXS at Rp16.838 with a -4.31% change and 99% sell order activity, KSM at Rp67.269 down 3.94%, and VET at Rp112 down 3.90% with 76% buy orders.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App